Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ZG005, which is being tested in combination with two other drugs, Etoposide and Cisplatin, for patients with advanced neuroendocrine carcinoma, a type of cancer that affects hormone-producing cells. The trial has two parts: the first part focuses on finding the safest dose of this combination, while the second part looks at how well it works in patients. The study is currently recruiting participants aged 18 to 70 who have been diagnosed with recurrent or metastatic neuroendocrine carcinoma and have a good performance status, meaning they can carry out daily activities with little to no difficulty.

If you join this trial, you can expect to receive close medical supervision and support throughout the study. To be eligible, you should not have any current problems with brain metastases (cancer spread to the brain) and should not have any other cancers within the last five years. It’s important that you fully understand the study and agree to participate voluntarily. This trial is a promising opportunity to explore a new treatment option for advanced neuroendocrine carcinoma, potentially helping improve outcomes for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fully understand the study and voluntarily sign the informed consent form.
• • Male or female 18-70 years of age.
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
• • Histologically confirmed recurrent or metastatic neuroendocrine carcinoma
• • Life expectancy ≥ 3 months.
• Exclusion Criteria:
• • Medical history, computed tomography or magnetic resonance imaging results indicate that existence of the central nervous system metastases;
• • Any other malignancy within 5 years.
• • participants were deemed unsuitable for participating in the study by the investigator for any reasons.